Loading ...
The presence of high - risk features for systemic spread on histopathological evaluation11promptedtreatment with adjuvant IVC
the use of malaria rapid diagnostic tests ( RDTsto preventpresumptive treatment with antimalarials
lifetime DanishsettingTreatment with sacubitril / valsartan
Data on the management of patients in the emergencysettingundergoing treatment with anticoagulants
a significant benefitresultingfrom treatment with aripiprazole
to stimulate the patient ’s immune system to target components on the cancer cells(passive) is designedTreatment with mAbs
Chlamydia and Ureaplasma Urealyticum Chen Xianliang(passive) Caused byTreatment with Jimei'an of Nongonococcal Urethritis
Third pair of panels : Confocal stacks of the central jaw of zebrafish labelled with CS-56 antibody at 4dpfleadstreatment with PNPX
with an antidepressant impact(passive) was discoveredTreatment with duloxetine
Speak to your physicianmust preventtreatment with Stilnox
a significantly greater decrease in total symptom score ( primary efficacy variable ... and in individual scores of inflammatory symptoms associated with the obstruction process ( headache , congestion , and facial pain ) compared with placebocauseda significantly greater decrease in total symptom score ( primary efficacy variable ... and in individual scores of inflammatory symptoms associated with the obstruction process ( headache , congestion , and facial pain ) compared with placebo
in a reduction in the frequency , duration , and severity of episodes of alternating hemiplegia , along with other therapeutic benefitsresultedin a reduction in the frequency , duration , and severity of episodes of alternating hemiplegia , along with other therapeutic benefits
to significant amelioration of negative symptoms and improvement of social functioningledto significant amelioration of negative symptoms and improvement of social functioning
in an improvement in positive psychotic symptomsresultedin an improvement in positive psychotic symptoms
in only 10 % higher relief in rates of remission from symptoms of MDD than adjunctive treatment with placebo.18 More significantly ... a comprehensive review article on the treatment of MDD found that patients benefited more from combined interpersonal psychotherapy and pharmacotherapy than from pharmacotherapy alone.19resultedin only 10 % higher relief in rates of remission from symptoms of MDD than adjunctive treatment with placebo.18 More significantly ... a comprehensive review article on the treatment of MDD found that patients benefited more from combined interpersonal psychotherapy and pharmacotherapy than from pharmacotherapy alone.19
in a favourable response to both psychotic symptoms and prolactinomahowever ... resultedin a favourable response to both psychotic symptoms and prolactinoma
to improvements in a broad range of symptoms included in the YMRS scale.17ledto improvements in a broad range of symptoms included in the YMRS scale.17
in potentially clinically meaningful increases in bone mass in the whole body as well as in the lumbar spine , which is particularly prone to fractures in pediatric patients with inflammatory conditions receiving steroid treatment for chronic rheumatic diseasemay resultin potentially clinically meaningful increases in bone mass in the whole body as well as in the lumbar spine , which is particularly prone to fractures in pediatric patients with inflammatory conditions receiving steroid treatment for chronic rheumatic disease
in a significant improvement of OCDresultedin a significant improvement of OCD
in significant improvement in the PANSS and Clinical Global Impression scoresresultedin significant improvement in the PANSS and Clinical Global Impression scores
in mild to moderate side effects and was well - tolerated my most participantsresultedin mild to moderate side effects and was well - tolerated my most participants
to a reduction in methamphetamine craving and use in patients diagnosed with methamphetamine dependenceleadsto a reduction in methamphetamine craving and use in patients diagnosed with methamphetamine dependence
to a statistically significant percent reduction in POS over placebo in baseline - adjusted POS frequency per 28 days and ≥50 % responder rateledto a statistically significant percent reduction in POS over placebo in baseline - adjusted POS frequency per 28 days and ≥50 % responder rate
in a decrease in mean BDI - II valuesresultedin a decrease in mean BDI - II values
in a significant increase in parameters such as OAT , % OAT , OAE , and % OAEresultedin a significant increase in parameters such as OAT , % OAT , OAE , and % OAE